AZN
NASDAQ
GB
AstraZeneca PLC - American Depositary Shares
$203.49
▲ +$2.76
(+1.38%)
Vol 2.0M
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$213.8B
P/E
30.6
ROE
21.8%
Margin
16.2%
D/E
71.11
Beta
0.86
Div Yield
1.77%
52W
$9574–$14206
Wall Street Consensus
36 analysts · Apr 202612
Strong Buy
17
Buy
5
Hold
2
Sell
0
Strong Sell
80.6%
Buy Rating
Price Chart
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $2.15 | $2.12 | $-0.03 |
| Sep 2025 | $2.35 | $2.38 | +$0.03 |
| Jun 2025 | $2.35 | $2.17 | $-0.18 |
| Mar 2025 | $2.28 | $2.49 | +$0.21 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $14.9B | $13.6B | $14.5B | $15.2B | $15.5B |
| Net Income | — | $1.5B | $2.9B | $2.5B | $2.5B | $2.3B |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 19.8% | 19.8% | 19.8% | 19.8% | 21.8% | 21.8% |
| P/E (TTM) | 25.45 | 29.72 | 28.13 | 30.84 | 30.10 | 30.65 |
| Net Margin | 17.0% | 14.7% | 14.7% | 14.7% | 16.2% | 16.2% |
| Gross Margin | 82.0% | 82.1% | 82.1% | 82.1% | 81.9% | 81.9% |
| D/E Ratio | 73.43 | 73.43 | 73.43 | 73.43 | 71.11 | 71.11 |
| Current Ratio | 0.86 | 0.86 | 0.86 | 0.86 | 0.88 | 0.88 |
Key Ratios
ROA (TTM)
8.6%
P/S (TTM)
4.96
P/B
5.4
EPS (TTM)
$6.02
CF/Share
$5.82
Rev Growth 3Y
+13.1%
52W High
$14206.00
52W Low
$9573.51
$9573.51
52-Week Range
$14206.00
Financial Health
Free Cash Flow
$1.1B
Net Debt
$23.9B
Cash
$5.7B
Total Debt
$29.6B
As of Dec 31, 2025
How does AZN compare to Pharmaceuticals peers?
Peer group: Large-cap Pharmaceuticals ($10B+) · 7 companies
AZN valuation vs Pharmaceuticals peers
P/E ratio
30.7
▲
68%
above
peers
(18.2)
vs Peers
vs Industry
Pricier
P/S ratio
5.0
▲
57%
above
peers
(3.2)
vs Peers
vs Industry
Overvalued
P/B ratio
5.4
▲
169%
above
peers
(2.0)
vs Peers
vs Industry
Overvalued
Div yield
1.8%
▼
42%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
AZN profitability vs Pharmaceuticals peers
ROE
21.8%
▲
88%
above
peers
(11.6%)
vs Peers
vs Industry
Top tier
Net margin
16.2%
▼
12%
below
peers
(18.4%)
vs Peers
vs Industry
Weak
Gross margin
81.9%
▲
13%
above
peers
(72.3%)
vs Peers
vs Industry
In line
ROA
8.6%
▲
107%
above
peers
(4.2%)
vs Peers
vs Industry
Below avg
AZN financial health vs Pharmaceuticals peers
D/E ratio
71.1
▲
0%
above
peers
(71.1)
vs Peers
vs Industry
In line
Current ratio
0.9
▼
47%
below
peers
(1.7)
vs Peers
vs Industry
Low liquidity
Beta
0.9
▲
0%
above
peers
(0.9)
vs Peers
vs Industry
Less volatile
AZN fundamentals radar
AZN
Peer median
Industry
AZN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AZN vs peers: key metrics
Dividends
$6.28
/ year
Feb 19, 2026
$2.1530
Aug 08, 2025
$1.0300
Feb 21, 2025
$2.1000
Aug 09, 2024
$1.0000
Feb 22, 2024
$1.9700
Aug 10, 2023
$0.9300
Feb 23, 2023
$1.9700
Aug 11, 2022
$0.9300